World first with multiple Covid-19 test machine : Page 2 of 3

September 25, 2020 //By Nick Flaherty
Bosch has reduced the test time for its Vivalytic machine to 39 minutes with five Covid-19 tests simultaneously in a world first
Bosch has reduced the test time for its Vivalytic machine to 39 minutes with five Covid-19 tests simultaneously in a world first
to be a tremendous help with this complex job. The rapid improvement of our technological capabilities shows what innovative achievements German companies can deliver in times of crisis.”

The test has a sensitivity of 98 percent and a specificity of 100 percent. To develop it, the Bosch subsidiary Bosch Healthcare Solutions joined forces with the German biotechnology company R-Biopharm – a leading provider of highly sensitive manual PCR tests. Randox Labs in northern Ireland that was the lab partner for the first version launched at the end of March after just six weeks’ development. This was a multiplex test that simultaneously checks samples for the SARS-CoV-2 virus and nine other respiratory diseases in two and a half hours.

This is comparable to the multiplex one hour test developed by DNAnudge in the UK thas has been shown a sensitivity of 94.4% accurate compared against standard NHS lab-based tests and a specificity of 100 percent to avoid false positives.

    “The decentralisation of mass testing is now being recognised as the key to addressing this unprecedented public health crisis, and these results very clearly support the use of CovidNudge as a highly accurate, rapid and near-patient testing solution that can be delivered on-the-spot and at scale, in both clinical and non-clinical settings," said Prof Chris Toumazou, CEO and co-founder of DnaNudge.

    The new, accelerated test using the Biopharm reagent is exclusively for Covid-19 to reduce the test time. The platform is open and supports the Randox reagents as well as the Biopharm reagents for the faster testing and for pooled tests says Bosch.

    “With our different coronavirus tests and variable analysis strategies, we open up a range of testing scenarios with a Vivalytic device – from screening all the way to supporting differential diagnosis for diseases with similar symptoms,” said Marc Meier, president of Bosch Healthcare Solutions.

    By the end of the year, Bosch wants to reach capacity for one million tests and says it is working closely with


    Vous êtes certain ?

    Si vous désactivez les cookies, vous ne pouvez plus naviguer sur le site.

    Vous allez être rediriger vers Google.